Phase I Study of Ofatumumab, a Human Anti-CD20 Antibody, in Japanese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

By Ogura Michinori   Hatake Kiyohiko   Tobinai Kensei   Uchida Toshiki   Suzuki Tatsuya   Terui Yasuhito   Yokoyama Masahiro   Maruyama Dai   Mori Masakazu   Jewell Roxanne C.   Katsura Koichi   Hotta Tomomitsu  

Japanese Journal of Clinical Oncology, Vol. 43, Iss. 5, 2013-05 ,pp. : 466-475

Oxford University Press

Access to resources Recommend Favorite

Anti-CD20 antibody induces the improvement of cytokine-induced killer cell activity via the STAT and MAPK/ERK signaling pathways

By            

Experimental and Therapeutic Medicine, Vol. 9, Iss. 4, 2015-01 ,pp. : 1215-1222

Spandidos Publications

Access to resources Recommend Favorite

Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-CELL chronic lymphocytic leukemia

By Cavalli-Björkman Nina   Ösby Eva   Lundin Jeanette   Kalin Mats   Österborg Anders   Gruber Astrid  

Medical Oncology, Vol. 19, Iss. 4, 2002-12 ,pp. : 277-280

Humana Press, Inc

Access to resources Recommend Favorite

The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance)

By Smith Sonali M.  

Leukemia and Lymphoma, Vol. 54, Iss. 7, 2013-07 ,pp. : 1405-1410

Informa Healthcare

Access to resources Recommend Favorite

Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM × anti-CD3): a phase I study

By Sebastian Martin   Passlick Bernward   Friccius-Quecke Hilke   Jäger Michael   Lindhofer Horst   Kanniess Frank   Wiewrodt Rainer   Thiel Eckhard   Buhl Roland   Schmittel Alexander  

Cancer Immunology, Immunotherapy, Vol. 56, Iss. 10, 2007-10 ,pp. : 1637-1644

Springer Publishing Company

Access to resources Recommend Favorite